← Leaderboards
Matthew Joel Feinstein
Northwestern University
$5,296,842
Attributed
$7,658,407
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,658,407 · 3
By mechanism
R01$7,658,407 · 3
Top collaborators
- Ivona Pandrea4 shared
- Edward Benjamin Thorp2 shared
Most similar at Northwestern University
Same institution · by research overlap
- Mary McGrae McDermott$74,643,817
- Jack J Jiang$16,467,793
- Todd B Parrish$4,304,754
- Samuel I Stupp$23,436,187
- Hossein Ardehali$24,656,316
Others in their field
Other Emerging Leaders on “Phenotype”
- Leonard Freedman · Leidos Biomedical Research, Inc.$68,463,085
- Yunda Huang · Fred Hutchinson Cancer Center$52,003,716
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Lynn Briscoe · Leidos Biomedical Research, Inc.$28,580,688
- Evan Z Macosko · Broad Institute, Inc.$28,218,682
- Badri N Vardarajan · University Of Miami School Of Medicine$23,982,327
Research focus
PhenotypeCardiovascular Disorder RiskTissuesCellsInflammatoryImmunePersonsResolutionEventInsightInflammationMonocyteHigh RiskGenesHeart FailureMortalityMultidisciplinaryFunctional DisorderAutopsyCardiacInvestigationImpairmentClinically RelevantComorbidity
Grant awards (12)
Integrated epidemiology of systemic and plaque-specific immunologic features of human atherosclerosis$788,083
R01 · FY2025 · HL · contact PI
Integrated epidemiology of systemic and plaque-specific immunologic features of human atherosclerosis$796,083
R01 · FY2024 · HL · contact PI
Immunologic, Inflammatory, and Clinical contributors to HIV-Related Heart Failure with Preserved Ejection Fraction (HFpEF)$707,690
R01 · FY2024 · HL · contact PI
Immunologic, Inflammatory, and Clinical contributors to HIV-Related Heart Failure with Preserved Ejection Fraction (HFpEF)$45,187
R01 · FY2024 · HL · contact PI
Myocardial Vulnerability to Ischemia-Induced Dysfunction and Heart Failure: The Impact of HIV/SIV, ART, and Targeted Immunotherapy$782,809
R01 · FY2023 · HL · contact PI
Immunologic, Inflammatory, and Clinical contributors to HIV-Related Heart Failure with Preserved Ejection Fraction (HFpEF)$733,395
R01 · FY2023 · HL · contact PI
Administrative Supplement to Immunologic, Inflammatory, and Clinical contributors to HIV-Related Heart Failure with Preserved Ejection Fraction$49,907
R01 · FY2023 · HL · contact PI
Myocardial Vulnerability to Ischemia-Induced Dysfunction and Heart Failure: The Impact of HIV/SIV, ART, and Targeted Immunotherapy$782,809
R01 · FY2022 · HL · contact PI
Immunologic, Inflammatory, and Clinical contributors to HIV-Related Heart Failure with Preserved Ejection Fraction (HFpEF)$737,451
R01 · FY2022 · HL · contact PI
Myocardial Vulnerability to Ischemia-Induced Dysfunction and Heart Failure: The Impact of HIV/SIV, ART, and Targeted Immunotherapy$774,257
R01 · FY2021 · HL · contact PI
Immunologic, Inflammatory, and Clinical contributors to HIV-Related Heart Failure with Preserved Ejection Fraction (HFpEF)$661,647
R01 · FY2021 · HL · contact PI
Myocardial Vulnerability to Ischemia-Induced Dysfunction and Heart Failure: The Impact of HIV/SIV, ART, and Targeted Immunotherapy$799,089
R01 · FY2020 · HL · contact PI